What pneumonia risk is associated with the inhaled corticosteroid in Fostair 100/6 inhalation solution in people with COPD?

The inhaled corticosteroid in Fostair 100/6 inhalation solution is associated with increased pneumonia incidence in people with COPD, including pneumonia requiring hospitalisation; evidence suggesting greater risk with higher steroid doses is inconclusive across studies, and differences in risk between inhaled corticosteroid products are not conclusively established.